Liv. 52^® (Tablets) Instructions for Use

Marketing Authorization Holder

Himalaya Wellness Company (India)

ATC Code

A05BA (Drugs for the treatment of liver diseases)

Dosage Form

Liv. 52^®

Tablets: 100 pcs.

Dosage Form, Packaging, and Composition

Liv. 52^®

Tablets of a greenish-gray color with inclusions of lighter and darker color, round, biconvex.

	1 tab.
Capparis spinosa root powder	65 mg
Cichorium intybus seed powder	65 mg
Solanum nigrum whole plant powder	32 mg
Powder of Terminalia arjuna bark	32 mg
Cassia occidentalis seed powder	16 mg
Achillea millefolium herb powder	16 mg
Tamarix gallica whole plant powder	16 mg
Iron (III) oxide	33 mg
Processed with steam extract from a mixture of medicinal raw materials: Eclipta alba Hassk (Eclipta alba whole plant), Phyllanthus amarus Schum. et. Thonn. (Phyllanthus niruri whole plant), Boerhaavia diffusa L. (Boerhaavia diffusa roots), Tinospora cordifolia Miers. (Tinospora cordifolia stems), Raphanus sativus L. (Raphanus sativus root vegetables), Emblica officinalis Gaertn. (Emblica officinalis fruits), Plumbago zeylanica L. (Plumbago zeylanica roots), Embelia ribes Burm.f. (Embelia ribes fruits), Terminalia chebula Retz.(Terminalia chebula fruit peel), Fumaria officinalis L. (Fumaria officinalis whole plant).

Excipients: magnesium stearate, microcrystalline cellulose, croscarmellose sodium, sodium carboxymethylcellulose.

100 pcs. – plastic bottles (1) – cardboard packs.

Clinical-Pharmacological Group

Herbal preparation with hepatoprotective and choleretic action

Pharmacotherapeutic Group

Hepatoprotective agent of plant origin

Pharmacological Action

A combined herbal preparation. It has hepatoprotective, antitoxic, anti-inflammatory, choleretic, antioxidant, and antianorexic action. It helps to improve the process of digestion and food absorption.

The hepatoprotective effect of Liv. 52^® is due to the antioxidant and membrane-stabilizing properties of its components. The drug increases the level of endogenous tocopherols in hepatocytes and the level of cytochrome P₄₅₀. Liv. 52^® stimulates the biosynthesis of proteins and phospholipids. It promotes the restoration of hepatocytes, reduces degenerative, fatty, and fibrotic changes, and enhances intracellular metabolism.

The drug regulates the level of blood plasma proteins, normalizing the albumin/globulin ratio. It ensures normalization of the levels of plasma transaminases, cholesterol, triglycerides, reducing the manifestations of dyslipidemia. It reduces bilirubin and alkaline phosphatase levels. It increases the liver’s ability to store glycogen.

It improves the colloidal properties of bile, preventing the formation of gallstones. It improves the contractile function of the gallbladder.

It stimulates hematopoiesis.

In alcoholic liver damage, the drug reduces the level of ethanol in the blood and urine; increases the activity of acetaldehyde dehydrogenase, which helps to reduce the level of acetaldehyde; prevents the binding of acetaldehyde to cell proteins, accelerating its excretion. By preventing the damaging effect of acetaldehyde on hepatocytes, the drug reduces the risk of developing a “hangover” syndrome.

Pharmacokinetics

The therapeutic effect of Liv. 52^® is due to the combined action of its components, so conducting kinetic observations is not possible.

Indications

Acute and chronic infectious, toxic, and drug-induced hepatitis;
Liver cirrhosis in adults;
Fatty hepatosis;
Anorexia;
Prevention of toxic liver damage (caused by antibiotics, antituberculosis drugs, antipyretics).

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
B15	Acute hepatitis A
B16	Acute hepatitis B
B17.1	Acute hepatitis C
B18.0	Chronic viral hepatitis B with delta-agent
B18.1	Chronic viral hepatitis B without delta-agent
B18.2	Chronic viral hepatitis C
K70	Alcoholic liver disease
K71	Toxic liver disease
K74	Fibrosis and cirrhosis of liver
K76.0	Fatty (change of) liver, not elsewhere classified
R63.0	Anorexia
Y40	Systemically acting antibiotics
Y41.1	Antimycobacterial drugs
Y45	Analgesics, antipyretics and anti-inflammatory drugs

ICD-11 code	Indication
1E50.0	Acute hepatitis A
1E50.1	Acute hepatitis B
1E50.2	Acute hepatitis C
1E51.0Z	Chronic hepatitis B, unspecified
1E51.1	Chronic viral hepatitis C
1E51.2	Chronic hepatitis D
4A85.00	Drug hypersensitivity-induced liver disease
DB92.0	Non-alcoholic fatty liver disease without steatohepatitis
DB92.Y	Other specified non-alcoholic fatty liver disease
DB92.Z	Non-alcoholic fatty liver disease, unspecified
DB93	Fibrosis or cirrhosis of liver
DB94.Z	Alcoholic liver disease, unspecified
DB95.Z	Drug-induced or toxic liver disease, unspecified
MG43.7	Anorexia
PL00	Drugs, medicaments or biological substances causing injury or harm in therapeutic use

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

For preventive purposes, the drug is prescribed as 2 tablets 2 times/day.

For therapeutic purposes, children over 6 years are prescribed 1-2 tablets 2-3 times/day, adults – 2-3 tablets 2-3 times/day.

The drug in the form of drops is prescribed for therapeutic and preventive purposes to children over 2 years as 10-20 drops 2 times/day, to adults – 80-160 drops (1-2 teaspoons) 2 times/day.

Adverse Reactions

Possible allergic reactions, dyspepsia.

Contraindications

Hypersensitivity to the components of the drug;
Pregnancy;
Lactation.

Use in Pregnancy and Lactation

The drug is contraindicated for use during pregnancy and lactation.

Pediatric Use

For therapeutic purposes, children over 6 years are prescribed 1-2 tablets 2-3 times/day.

The drug in the form of drops is prescribed for therapeutic and preventive purposes to children over 2 years as 10-20 drops 2 times/day

Special Precautions

The drug should be prescribed with caution to patients with acute gastrointestinal diseases.

Liv. 52^® K (dosage form – drops) does not contain ethyl alcohol and can be used in children with liver and biliary tract diseases.

Overdose

There is no information on overdose of Liv.52.

Drug Interactions

Drug interactions of Liv.52 have not been described.

Storage Conditions

The drug should be stored in a dry place at a temperature from 10°C (50°F) to 30°C (86°F).

Shelf Life

Shelf life – 3 years.

Dispensing Status

The drug is approved for use as an over-the-counter product.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer